<DOC>
	<DOCNO>NCT02342184</DOCNO>
	<brief_summary>This study carry assess efficacy GB-0998 ( intravenous immunoglobulin ; 400mg/kg/day five day ) treatment Guillain-Barré Syndrome base change Hughes Functional Grade ( FG ) primary endpoint , addition , assess safety GB-0998 .</brief_summary>
	<brief_title>Efficacy Safety Study GB-0998 Guillain-Barré Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Guillain-Barre Syndrome</mesh_term>
	<criteria>1 . In principle , patient able receive treatment within 2 week ( limit 4 week ) start symptom . 2 . Patients predominant motor neuropathy FG grade 4 grade 5 ( symptom progressive , patient FG grade 3 involve study ) . 3 . Patients plasmapheresis , steroid immune globulin therapy operation onset . 1 . Patients anamnesis shock hypersensitivity GB0998 . 2 . Patients diagnose hereditary fructose intolerance . 3 . Patients impaired peripheral neuropathy except GuillainBarré syndrome . 4 . Patients history volatile organic solvent abuse , abnormal porphyrin metabolism , history pharynx cutaneous diphtheria , plumbism , poliomyelitis , botulism , hysterical paralysis , toxic neuropathy . 5 . Patients receive treatment malignant tumor . 6 . Patients administer immunoglobulin within 8 week inform consent . 7 . Patients diagnose IgA deficiency past history . 8 . Patients severe renal disorder decrease cardiac function . 9 . Patients anamnesis cerebro cardiovascular disorder , symptom disease . 10 . Patients high risk thromboembolism . 11 . Pregnant , lactating , probably pregnant patient . 12 . Patients administer investigational drug within 12 week consent .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>